Irena Tan1, Thomas E Stinchcombe2,3, Neal E Ready2,3, Jeffrey Crawford2,3, Michael B Datto4, Rebecca J Nagy5, Richard B Lanman5, Lin Gu2, Jeffrey M Clarke2,3. 1. Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA. 2. Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. 3. Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. 4. Department of Pathology, Duke University Medical Center, Durham, NC, USA. 5. Guardant Health, Inc., Penobscot Dr, Redwood City, CA, USA.
Abstract
BACKGROUND: Data describing therapeutic outcomes in patients with non-small cell lung cancers (NSCLC) with BRAF mutations remains limited. METHODS: We conducted a retrospective cohort study of 31 patients with metastatic NSCLC treated at Duke University Hospital who had been identified by next-generation sequencing methods to bear a BRAF mutation in their tumor in order to evaluate clinical response to immunotherapy and chemotherapy. RESULTS: Sixty-five percent of patients identified in this cohort were current or former smokers. Fourteen (45.2%) of patients had a BRAF V600E mutation and 17 (54.8%) had a non-V600E mutation. Median progression-free survival (PFS) in the 23 patients who received first-line chemotherapy was 6.4 months [95% confidence interval (CI), 2.3 to 13.0]. Overall survival (OS) in patients who received first-line chemotherapy showed a median survival of 18 months (95% CI, 7.4 to 28.6). OS comparing patients who had never received immunotherapy at any point was 18.4 months (95% CI, 4.1 to NE) compared to 19.0 months (95% CI, 9.9 to 28.6) in those who had received immunotherapy. We did not find a statistically significant difference in OS in patients with BRAF V600E, BRAF amplification, or non-V600E mutations. There was also no difference in OS in patients treated with targeted BRAF inhibitors compared to those who were not treated with targeted BRAF inhibitors. CONCLUSIONS: We describe therapeutic outcomes for patients with metastatic NSCLC with BRAF mutations treated with either cytotoxic chemotherapy or immunotherapy. Although the sample size is small, the survival curves do not suggest improved clinical activity in this population when treated with immunotherapy.
BACKGROUND: Data describing therapeutic outcomes in patients with non-small cell lung cancers (NSCLC) with BRAF mutations remains limited. METHODS: We conducted a retrospective cohort study of 31 patients with metastatic NSCLC treated at Duke University Hospital who had been identified by next-generation sequencing methods to bear a BRAF mutation in their tumor in order to evaluate clinical response to immunotherapy and chemotherapy. RESULTS: Sixty-five percent of patients identified in this cohort were current or former smokers. Fourteen (45.2%) of patients had a BRAF V600E mutation and 17 (54.8%) had a non-V600E mutation. Median progression-free survival (PFS) in the 23 patients who received first-line chemotherapy was 6.4 months [95% confidence interval (CI), 2.3 to 13.0]. Overall survival (OS) in patients who received first-line chemotherapy showed a median survival of 18 months (95% CI, 7.4 to 28.6). OS comparing patients who had never received immunotherapy at any point was 18.4 months (95% CI, 4.1 to NE) compared to 19.0 months (95% CI, 9.9 to 28.6) in those who had received immunotherapy. We did not find a statistically significant difference in OS in patients with BRAF V600E, BRAF amplification, or non-V600E mutations. There was also no difference in OS in patients treated with targeted BRAF inhibitors compared to those who were not treated with targeted BRAF inhibitors. CONCLUSIONS: We describe therapeutic outcomes for patients with metastatic NSCLC with BRAF mutations treated with either cytotoxic chemotherapy or immunotherapy. Although the sample size is small, the survival curves do not suggest improved clinical activity in this population when treated with immunotherapy.
Entities:
Keywords:
Immunotherapy; V600E; amplification; chemotherapy; retrospective cohort study
Authors: Katsuhiko Naoki; Tzu-Hsiu Chen; William G Richards; David J Sugarbaker; Matthew Meyerson Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: Hongbin Ji; Zhenxiong Wang; Samanthi A Perera; Danan Li; Mei-Chih Liang; Sara Zaghlul; Kate McNamara; Liang Chen; Mitchell Albert; Yanping Sun; Ruqayyah Al-Hashem; Lucian R Chirieac; Robert Padera; Roderick T Bronson; Roman K Thomas; Levi A Garraway; Pasi A Jänne; Bruce E Johnson; Lynda Chin; Kwok-Kin Wong Journal: Cancer Res Date: 2007-05-15 Impact factor: 12.701
Authors: Marcia S Brose; Patricia Volpe; Michael Feldman; Madhu Kumar; Irum Rishi; Renee Gerrero; Eugene Einhorn; Meenhard Herlyn; John Minna; Andrew Nicholson; Jack A Roth; Steven M Albelda; Helen Davies; Charles Cox; Graham Brignell; Philip Stephens; P Andrew Futreal; Richard Wooster; Michael R Stratton; Barbara L Weber Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo Journal: Curr Oncol Rep Date: 2020-04-16 Impact factor: 5.075
Authors: Michelle F Green; Jonathan L Bell; Christopher B Hubbard; Shannon J McCall; Matthew S McKinney; Jinny E Riedel; Carolyn S Menendez; James L Abbruzzese; John H Strickler; Michael B Datto Journal: JCO Precis Oncol Date: 2021-09-16